<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520363</url>
  </required_header>
  <id_info>
    <org_study_id>FD-004247-01</org_study_id>
    <nct_id>NCT01520363</nct_id>
  </id_info>
  <brief_title>Placebo Controlled Trial of Dextromethorphan in Rett Syndrome</brief_title>
  <acronym>PCTDMRTT</acronym>
  <official_title>Placebo Controlled Trial of Dextromethorphan in Rett Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Johns Hopkins Institute for Clinical and Translational Research (ICTR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dr. Sakkubai Naidu, Principal Investigator, is initiating a double blinded placebo controlled
      clinical drug trial using dextromethorphan (DM) in Rett Syndrome (RTT), at the Pediatric
      Clinical Research Unit (PCRU) of the Johns Hopkins Hospital/Kennedy Krieger Institute.
      Funding source , FDA-00PD

      It has been shown that receptors for a certain brain chemical called glutamate, in particular
      the NMDA type, are increased in the brain of young RTT patients (&lt;10 years of age). This
      chemical and its receptors, when in excess, cause harmful over-stimulation of nerve cells in
      the brain, contributing in part to the seizures, behavioral problems, and learning
      disabilities in RTT.

      The investigators propose to initiate a specific treatment using DM to counter/block the
      effects of this brain chemical and its excessive receptors to improve the ill effects of
      increased glutamate/NMDA receptors, because of DM's identified ability to block NMDA
      receptors. DM is available for human consumption. Infants and children with respiratory
      infections and cough, as well as non-ketotic hyperglycinemia, are treated with DM, which has
      been well tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will last for 3 months and will be limited to MECP2 mutation-positive children, one
      year - 9.99 years of age. This clinical trial, which is a placebo-controlled study, will
      randomize patients to the drug or placebo to determine the benefits of DM vs placebo on
      cognition, behavior, or seizures if present.

      Your child will stay twice in the Pediatric Clinical Research Unit (PCRU) at Johns Hopkins
      ICTR, for 3 days during each admission. The first hospital stay will be for 3 days, before
      she starts the DM or placebo. The follow-up 3-day hospital stay will be 3 months after she
      starts taking DM or placebo. There will also be two interim follow up evaluations at 2 weeks
      and 1 month after she starts taking the DM or placebo consisting of a neurological
      evaluation, EKG, and blood work, which can take place at your local doctor's office or at
      Johns Hopkins, and will be paid for by this study. Our research nurse or research associate
      will contact you at least weekly during the first month, and at least monthly thereafter
      until the end of the 3-month study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Actual">October 26, 2016</completion_date>
  <primary_completion_date type="Actual">October 26, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mullen; Visual Reception Sub-scale Scores, Pre- and Post-Intervention</measure>
    <time_frame>Initial evaluation and at the end of the 3 month trial</time_frame>
    <description>The Mullen Scales of Early Learning (MULLEN) Visual reception subscale raw scores range from Minimum=0 to Maximum=50. A higher score is a better outcome. Age equivalents from 1 month to 70 months can be computed for each subscale separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Mullen; Fine Motor Sub-scale Scores, Pre- and Post-Intervention</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The Mullen Scales of Early Learning (MULLEN) Fine motor scale raw scores range from Minimum=0 to Maximum=49. A higher score is a better outcome. Age equivalents from 1 month to 70 months can be computed for each subscale separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Mullen; Receptive Language Subscale Scores, Pre- and Post-Intervention</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The Mullen Scales of Early Learning (MULLEN) Receptive Language scale raw scores range from Minimum=0 to Maximum=50. A higher score is a better outcome. Age equivalents from 1 month to 70 months can be computed for each subscale separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Mullen, Expressive Language Sub-scale Scores, Pre- and Post-Intervention</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The Mullen Scales of Early Learning (MULLEN) Expressive Language scale raw scores range from Minimum=0 to Maximum=50. A higher score is a better outcome. Age equivalents from 1 month to 70 months can be computed for each subscale separately.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in VABS: Motor Skills Domain Scores, Pre- and Post-Intervention</measure>
    <time_frame>Baseline evaluation and at the end of the 3 month study</time_frame>
    <description>Vineland Adaptive Behavior Scales-II (VABS): Motor Skills Domain Scores individual items are scored on a Likert scale from 2=Usually, 1=Sometimes or Partially, 0= Seldom or Never. Motor Skills Domain raw scores range from: Minimum=0 to Maximum=100. A higher score is a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VABS:Daily Living Skills Domain Scores, Pre- and Post-Intervention</measure>
    <time_frame>Baseline and at the end of the 3 month trial</time_frame>
    <description>Vineland Adaptive Behavior Scales-II (VABS): Daily Living Skills Domain individual items are scored on a Likert scale from 2=Usually, 1=Sometimes or Partially, 0= Seldom or Never. The Daily Living Skills Domain measures personal behavior as well as domestic and community interaction skills. Daily Living Skills Domain raw scores range from Minimum=0 to Maximum=218.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VABS: Socialization Domain Scores, Pre- and Post-Intervention</measure>
    <time_frame>Baseline and at the end of the 3 month trial</time_frame>
    <description>Vineland Adaptive Behavior Scales-II (VABS): Socialization Domain. Critical behaviors are scored on a Likert scale from 2=Usually, 1=Sometimes or Partially, 0= Seldom or Never. Socialization Domain raw scores range from: Minimum=0 to Maximum=152. A higher score is a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VABS:Communication Domain Scores, Pre- and Post-Intervention</measure>
    <time_frame>Baseline and at the end of the 3 month trial</time_frame>
    <description>Vineland Adaptive Behavior Scales (VABS)-II Communication Domain Scores. The Communication Domain evaluates the receptive, expressive, and written communication skills of the child. Critical behaviors in each Subdomain item are rated as 2=Usually, 1=Sometimes or Partially, 0= Seldom or Never. Communication Domain raw scores range from: Minimum=0 to Maximum=198. A higher score is a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ghuman-Folstein Screen for Social Interaction (SSI) Score, Pre- and Post-Intervention.</measure>
    <time_frame>Initial evaluation and at the end of the 3 month study. The test lasts 45 minutes</time_frame>
    <description>The Ghuman-Folstein Screen for Social Interaction (SSI) assesses the change in behavior and temperament dysregulation as a total score.
The score ranges from 0-162, with 0 being most Impaired /has the strongest autism features and 162 having no impairment/no autism features.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rett Syndrome Behavior Questionnaire Score, Pre- and Post-Intervention</measure>
    <time_frame>Initial evaluation and at the end of the 3 month study</time_frame>
    <description>The Rett Syndrome Behavior Questionnaire (RSBQ) total score was assessed. The total score ranges from 0 to 90, with 0 exhibiting no Rett syndrome related symptoms and 90 showing the greatest amount of symptoms (worse outcome).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in PedsQL School Functioning Subscale Score, Pre- and Post-Intervention</measure>
    <time_frame>Baseline evaluation and at the end of the 3 month study</time_frame>
    <description>Pediatric Quality of Life Inventory (PedsQL version 4). School Functioning subscale. 5-point Likert scale from 0 (Never) to 4 (Almost always); Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better Health Related Quality of Life (QOL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in PedsQL Total Score, Pre- and Post-Intervention</measure>
    <time_frame>Baseline evaluation and at the end of the 3 month study</time_frame>
    <description>Pediatric Quality of Life Inventory (PedsQL version 4) total score. Each item is rated on a 5-point Likert scale from 0 (Never) to 4 (Almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. The Total Score is the sum of all the items over the number of items answered on all the Scales. Higher scores indicate better HRQOL.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in PedsQL Social Functioning Subscale Score, Pre- and Post-Intervention</measure>
    <time_frame>Baseline and at the end of the 3 month trial</time_frame>
    <description>Pediatric Quality of Life Inventory (PedsQL version 4). Social Functioning subscale. 5-point Likert scale from 0 (Never) to 4 (Almost always); Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better Health Related Quality of Life (QOL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in PedsQL Emotional Functioning Subscale Score, Pre- and Post-Intervention</measure>
    <time_frame>Baseline evaluation and at the end of the 3 month study</time_frame>
    <description>Pediatric Quality of Life Inventory (PedsQL version 4). Emotional Functioning subscale. 5-point Likert scale from 0 (Never) to 4 (Almost always); Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better Health Related Quality of Life (QOL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in PedsQL Physical Functioning Subscale Score, Pre- and Post-Intervention</measure>
    <time_frame>Initial evaluation and at the end of the 3 month study</time_frame>
    <description>Pediatric Quality of Life Inventory (PedsQL version 4). Physical Functioning subscale. 5-point Likert scale from 0 (Never) to 4 (Almost always); Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better Health Related Quality of Life (QOL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Seizure Frequency, Pre- and Post-Intervention, 0-4 Year Age Group</measure>
    <time_frame>Baseline evaluation and at the end of the 3 month study</time_frame>
    <description>Change in Frequency of seizure count baseline to follow-up for children aged 0-4 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Seizure Frequency, Pre-and Post-Intervention, 5-10 Year Age Group</measure>
    <time_frame>Baseline evaluation and at the end of the 3 month study</time_frame>
    <description>Change in Frequency of seizures baseline to follow-up for children aged 5-10 years</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Rett Syndrome</condition>
  <arm_group>
    <arm_group_label>Study drug-dextromethorphan (DM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MECP2 mutation positive subjects randomized to receive DM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>MECP2 positive subjects randomized to the placebo compound</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dextromethorphan</intervention_name>
    <description>The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.</description>
    <arm_group_label>Study drug-dextromethorphan (DM)</arm_group_label>
    <other_name>Delsym</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and females who have classic or atypical RTT with a proven mutation in the MECP2
             gene;

          -  subjects must be between one year - 10 years of age.

        Exclusion Criteria:

          -  those without an established mutation in the MECP2 gene;

          -  those with mutations in the MECP2 gene but who have had brain resection or surgical
             intervention; for example, tumor, hydrocephalus, severe head trauma; or, an associated
             severe medical illnesses such as vasculopathies, malignancies, diabetes, thyroid
             dysfunction, etc;

          -  those on medications that could interact with DM, e.g. MAO inhibitors, SSRI,
             sibutramine etc. to avoid a serotonin syndrome; quinidine and drugs metabolized by the
             CYP450 isoform CYP2D6 (e.g. amiodarone, haloperidol, propafenone, thioridazine);

          -  those proven to be intermediate or slow metabolizers of DM;

          -  those with reported adverse reactions to DM;

          -  those whose pregnancy test is positive;

          -  those showing poor compliance with any aspect of the study;

          -  foster children.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sakkubai R Naidu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Kennedy Krieger Institute and Johns Hopkins SOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Johns Hopkins Institute for Clinical and Translational Research</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>January 25, 2012</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2012</study_first_posted>
  <results_first_submitted>July 31, 2018</results_first_submitted>
  <results_first_submitted_qc>September 25, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2018</results_first_posted>
  <disposition_first_submitted>January 24, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 24, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 26, 2018</disposition_first_posted>
  <last_update_submitted>November 7, 2018</last_update_submitted>
  <last_update_submitted_qc>November 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</investigator_affiliation>
    <investigator_full_name>SakkuBai Naidu, M.D.</investigator_full_name>
    <investigator_title>Professor of Neurology and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Rett syndrome</keyword>
  <keyword>RTT</keyword>
  <keyword>MECP2</keyword>
  <keyword>dextromethorphan</keyword>
  <keyword>DM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rett Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 12, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT01520363/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 57 participants were consented. Of these 5 were slow metabolizers who did not meet post consent eligibility criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Drug-dextromethorphan (DM)</title>
          <description>MECP2 mutation positive subjects randomized to receive DM
dextromethorphan: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>MECP2 positive subjects randomized to the placebo compound
placebo: The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Drug-dextromethorphan (DM)</title>
          <description>MECP2 mutation positive subjects randomized to receive DM
dextromethorphan: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>MECP2 positive subjects randomized to the placebo compound
placebo: The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.75" spread="2.52"/>
                    <measurement group_id="B2" value="4.91" spread="1.91"/>
                    <measurement group_id="B3" value="4.83" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mullen; Visual Reception Sub-scale Scores, Pre- and Post-Intervention</title>
        <description>The Mullen Scales of Early Learning (MULLEN) Visual reception subscale raw scores range from Minimum=0 to Maximum=50. A higher score is a better outcome. Age equivalents from 1 month to 70 months can be computed for each subscale separately.</description>
        <time_frame>Initial evaluation and at the end of the 3 month trial</time_frame>
        <population>Mutation positive participants who are fast metabolizers at baseline. 2 were noncompliant and removed from the study drug group. At 3 months 22 were analyzed in the study drug group and 25 in the placebo group due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive DM at baseline
dextromethorphan: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo at baseline
placebo: The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug Group at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to DM at 3 months</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to placebo at 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mullen; Visual Reception Sub-scale Scores, Pre- and Post-Intervention</title>
          <description>The Mullen Scales of Early Learning (MULLEN) Visual reception subscale raw scores range from Minimum=0 to Maximum=50. A higher score is a better outcome. Age equivalents from 1 month to 70 months can be computed for each subscale separately.</description>
          <population>Mutation positive participants who are fast metabolizers at baseline. 2 were noncompliant and removed from the study drug group. At 3 months 22 were analyzed in the study drug group and 25 in the placebo group due to incomplete data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.45" spread="3.419"/>
                    <measurement group_id="O2" value="6.61" spread="6.308"/>
                    <measurement group_id="O3" value="6.64" spread="7.135"/>
                    <measurement group_id="O4" value="6.57" spread="5.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.211</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=21</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.182</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.294</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.086</ci_lower_limit>
            <ci_upper_limit>.722</ci_upper_limit>
            <other_analysis_desc>t= -1.291; p=.211</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.949</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=22</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>.043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.670</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.345</ci_lower_limit>
            <ci_upper_limit>1.432</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Mullen; Fine Motor Sub-scale Scores, Pre- and Post-Intervention</title>
        <description>The Mullen Scales of Early Learning (MULLEN) Fine motor scale raw scores range from Minimum=0 to Maximum=49. A higher score is a better outcome. Age equivalents from 1 month to 70 months can be computed for each subscale separately.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <population>Mutation positive participants who are fast metabolizers at baseline. 2 were noncompliant and removed from the study drug group. At 3 months 22 were analyzed in the study drug group and 25 in the placebo group due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive DM at baseline
dextromethorphan: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo at baseline
placebo: The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug Group at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to DM at 3 months</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to placebo at 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mullen; Fine Motor Sub-scale Scores, Pre- and Post-Intervention</title>
          <description>The Mullen Scales of Early Learning (MULLEN) Fine motor scale raw scores range from Minimum=0 to Maximum=49. A higher score is a better outcome. Age equivalents from 1 month to 70 months can be computed for each subscale separately.</description>
          <population>Mutation positive participants who are fast metabolizers at baseline. 2 were noncompliant and removed from the study drug group. At 3 months 22 were analyzed in the study drug group and 25 in the placebo group due to incomplete data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.38" spread="5.5"/>
                    <measurement group_id="O2" value="7.00" spread="6.474"/>
                    <measurement group_id="O3" value="5.05" spread="6.103"/>
                    <measurement group_id="O4" value="7.04" spread="6.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.541</p_value>
            <p_value_desc>df=20</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>df=20</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.333</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.456</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.785</ci_lower_limit>
            <ci_upper_limit>1.451</ci_upper_limit>
            <other_analysis_desc>t=0.622; p=.541</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.946</p_value>
            <p_value_desc>df=23</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-.042</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.956</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.290</ci_lower_limit>
            <ci_upper_limit>1.206</ci_upper_limit>
            <other_analysis_desc>t=-.069; p=0.946</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Mullen; Receptive Language Subscale Scores, Pre- and Post-Intervention</title>
        <description>The Mullen Scales of Early Learning (MULLEN) Receptive Language scale raw scores range from Minimum=0 to Maximum=50. A higher score is a better outcome. Age equivalents from 1 month to 70 months can be computed for each subscale separately.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <population>Mutation positive participants who are fast metabolizers at baseline. 2 were noncompliant and removed from the study drug group. At 3 months 22 were analyzed in the study drug group and 25 in the placebo group due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive DM at baseline
dextromethorphan: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo at baseline
placebo: The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug Group at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to DM at 3 months</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to placebo at 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mullen; Receptive Language Subscale Scores, Pre- and Post-Intervention</title>
          <description>The Mullen Scales of Early Learning (MULLEN) Receptive Language scale raw scores range from Minimum=0 to Maximum=50. A higher score is a better outcome. Age equivalents from 1 month to 70 months can be computed for each subscale separately.</description>
          <population>Mutation positive participants who are fast metabolizers at baseline. 2 were noncompliant and removed from the study drug group. At 3 months 22 were analyzed in the study drug group and 25 in the placebo group due to incomplete data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="5.307"/>
                    <measurement group_id="O2" value="6.95" spread="5.269"/>
                    <measurement group_id="O3" value="6.68" spread="5.472"/>
                    <measurement group_id="O4" value="6.55" spread="6.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.736</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=21</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.227</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.116</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.609</ci_lower_limit>
            <ci_upper_limit>1.154</ci_upper_limit>
            <other_analysis_desc>t=-0.342; p=0.736</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.589</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.409</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.500</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.143</ci_lower_limit>
            <ci_upper_limit>1.961</ci_upper_limit>
            <other_analysis_desc>t=0.548; p=0.589</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Mullen, Expressive Language Sub-scale Scores, Pre- and Post-Intervention</title>
        <description>The Mullen Scales of Early Learning (MULLEN) Expressive Language scale raw scores range from Minimum=0 to Maximum=50. A higher score is a better outcome. Age equivalents from 1 month to 70 months can be computed for each subscale separately.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <population>Mutation positive participants who are fast metabolizers at baseline. 2 were noncompliant and removed from the study drug group. At 3 months 22 were analyzed in the study drug group and 25 in the placebo group due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive DM at baseline
dextromethorphan: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo at baseline
placebo: The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug Group at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to DM at 3 months</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to placebo at 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mullen, Expressive Language Sub-scale Scores, Pre- and Post-Intervention</title>
          <description>The Mullen Scales of Early Learning (MULLEN) Expressive Language scale raw scores range from Minimum=0 to Maximum=50. A higher score is a better outcome. Age equivalents from 1 month to 70 months can be computed for each subscale separately.</description>
          <population>Mutation positive participants who are fast metabolizers at baseline. 2 were noncompliant and removed from the study drug group. At 3 months 22 were analyzed in the study drug group and 25 in the placebo group due to incomplete data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" spread="3.665"/>
                    <measurement group_id="O2" value="6.73" spread="3.8"/>
                    <measurement group_id="O3" value="6.76" spread="5.504"/>
                    <measurement group_id="O4" value="7.29" spread="7.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=20</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.429</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.203</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.886</ci_lower_limit>
            <ci_upper_limit>0.029</ci_upper_limit>
            <other_analysis_desc>t=-2.044; p=0.05</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.958</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.042</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.862</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.589</ci_lower_limit>
            <ci_upper_limit>1.672</ci_upper_limit>
            <other_analysis_desc>t=0.053; p=0.958</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in VABS: Motor Skills Domain Scores, Pre- and Post-Intervention</title>
        <description>Vineland Adaptive Behavior Scales-II (VABS): Motor Skills Domain Scores individual items are scored on a Likert scale from 2=Usually, 1=Sometimes or Partially, 0= Seldom or Never. Motor Skills Domain raw scores range from: Minimum=0 to Maximum=100. A higher score is a better outcome.</description>
        <time_frame>Baseline evaluation and at the end of the 3 month study</time_frame>
        <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive DM (dextromethorphan) at baseline: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo compound at baseline. The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug-dextromethorphan (DM) at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to receive DM (dextromethorphan) who completed study assessments at the 3 month time point.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group at 3 Months</title>
            <description>MECP2 positive subjects randomized to the placebo compound who completed the assessments at the 3 month time point.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VABS: Motor Skills Domain Scores, Pre- and Post-Intervention</title>
          <description>Vineland Adaptive Behavior Scales-II (VABS): Motor Skills Domain Scores individual items are scored on a Likert scale from 2=Usually, 1=Sometimes or Partially, 0= Seldom or Never. Motor Skills Domain raw scores range from: Minimum=0 to Maximum=100. A higher score is a better outcome.</description>
          <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.86" spread="3.821"/>
                    <measurement group_id="O2" value="11.36" spread="4.838"/>
                    <measurement group_id="O3" value="9.64" spread="3.959"/>
                    <measurement group_id="O4" value="11.12" spread="4.755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.488</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=21</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.227</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.510</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.442</ci_lower_limit>
            <ci_upper_limit>0.897</ci_upper_limit>
            <other_analysis_desc>t=0.706; p=0.488</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.442</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=24</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.24</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.535</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.394</ci_lower_limit>
            <ci_upper_limit>0.874</ci_upper_limit>
            <other_analysis_desc>t=0.782; p=0.442</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in VABS:Daily Living Skills Domain Scores, Pre- and Post-Intervention</title>
        <description>Vineland Adaptive Behavior Scales-II (VABS): Daily Living Skills Domain individual items are scored on a Likert scale from 2=Usually, 1=Sometimes or Partially, 0= Seldom or Never. The Daily Living Skills Domain measures personal behavior as well as domestic and community interaction skills. Daily Living Skills Domain raw scores range from Minimum=0 to Maximum=218.</description>
        <time_frame>Baseline and at the end of the 3 month trial</time_frame>
        <population>52 MECP2 Mutation positive participants who are fast metabolizers were enrolled in the study. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive DM (dextromethorphan) at baseline: The DM group took 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo compound at baseline: The placebo was dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist dispensed the placebo to the participants.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug-dextromethorphan (DM) at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to receive DM (dextromethorphan) who completed the study at 3 months</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group at 3 Months</title>
            <description>MECP2 positive subjects randomized to the placebo compound were still active in the study at 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VABS:Daily Living Skills Domain Scores, Pre- and Post-Intervention</title>
          <description>Vineland Adaptive Behavior Scales-II (VABS): Daily Living Skills Domain individual items are scored on a Likert scale from 2=Usually, 1=Sometimes or Partially, 0= Seldom or Never. The Daily Living Skills Domain measures personal behavior as well as domestic and community interaction skills. Daily Living Skills Domain raw scores range from Minimum=0 to Maximum=218.</description>
          <population>52 MECP2 Mutation positive participants who are fast metabolizers were enrolled in the study. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.64" spread="6.939"/>
                    <measurement group_id="O2" value="21.00" spread="5.307"/>
                    <measurement group_id="O3" value="20.95" spread="6.388"/>
                    <measurement group_id="O4" value="19.84" spread="4.589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.182</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=21</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.682</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.317</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.346</ci_lower_limit>
            <ci_upper_limit>1.709</ci_upper_limit>
            <other_analysis_desc>t=1.380; p=0.182</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.005</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=24</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.160</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.864</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.391</ci_lower_limit>
            <ci_upper_limit>1.929</ci_upper_limit>
            <other_analysis_desc>t=3.112; p=0.005</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in VABS: Socialization Domain Scores, Pre- and Post-Intervention</title>
        <description>Vineland Adaptive Behavior Scales-II (VABS): Socialization Domain. Critical behaviors are scored on a Likert scale from 2=Usually, 1=Sometimes or Partially, 0= Seldom or Never. Socialization Domain raw scores range from: Minimum=0 to Maximum=152. A higher score is a better outcome.</description>
        <time_frame>Baseline and at the end of the 3 month trial</time_frame>
        <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive DM (dextromethorphan) at baseline: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists dispensed the DM to the study participants.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo compound at baseline: The placebo was dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist dispensed the placebo to the participants.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug-dextromethorphan (DM) at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to receive DM (dextromethorphan) at 3 month time period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to receive DM placebo at 3 month time period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VABS: Socialization Domain Scores, Pre- and Post-Intervention</title>
          <description>Vineland Adaptive Behavior Scales-II (VABS): Socialization Domain. Critical behaviors are scored on a Likert scale from 2=Usually, 1=Sometimes or Partially, 0= Seldom or Never. Socialization Domain raw scores range from: Minimum=0 to Maximum=152. A higher score is a better outcome.</description>
          <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.14" spread="5.557"/>
                    <measurement group_id="O2" value="22.96" spread="4.954"/>
                    <measurement group_id="O3" value="24.05" spread="6.514"/>
                    <measurement group_id="O4" value="22.48" spread="5.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>.091</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.504</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.463</ci_lower_limit>
            <ci_upper_limit>1.644</ci_upper_limit>
            <other_analysis_desc>t=0.122; p=0.90</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.356</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=24</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.480</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.551</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.573</ci_lower_limit>
            <ci_upper_limit>1.533</ci_upper_limit>
            <other_analysis_desc>t=0.941; p=0.356</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in VABS:Communication Domain Scores, Pre- and Post-Intervention</title>
        <description>Vineland Adaptive Behavior Scales (VABS)-II Communication Domain Scores. The Communication Domain evaluates the receptive, expressive, and written communication skills of the child. Critical behaviors in each Subdomain item are rated as 2=Usually, 1=Sometimes or Partially, 0= Seldom or Never. Communication Domain raw scores range from: Minimum=0 to Maximum=198. A higher score is a better outcome.</description>
        <time_frame>Baseline and at the end of the 3 month trial</time_frame>
        <population>52 MECP2 Mutation positive participants who are fast metabolizers were enrolled at baseline. Two participants in the baseline DM group were noncompliant and removed from the study. At 3 months 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive DM (dextromethorphan) at baseline: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo compound
placebo: The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug-dextromethorphan (DM) at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to receive DM (dextromethorphan) and active in study at 3 month time point.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to receive Placebo and active in study at 3 month time point.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VABS:Communication Domain Scores, Pre- and Post-Intervention</title>
          <description>Vineland Adaptive Behavior Scales (VABS)-II Communication Domain Scores. The Communication Domain evaluates the receptive, expressive, and written communication skills of the child. Critical behaviors in each Subdomain item are rated as 2=Usually, 1=Sometimes or Partially, 0= Seldom or Never. Communication Domain raw scores range from: Minimum=0 to Maximum=198. A higher score is a better outcome.</description>
          <population>52 MECP2 Mutation positive participants who are fast metabolizers were enrolled at baseline. Two participants in the baseline DM group were noncompliant and removed from the study. At 3 months 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.05" spread="4.146"/>
                    <measurement group_id="O2" value="18.08" spread="4.261"/>
                    <measurement group_id="O3" value="17.91" spread="5.032"/>
                    <measurement group_id="O4" value="17.96" spread="4.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.836</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.136</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.060</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.220</ci_lower_limit>
            <ci_upper_limit>1.493</ci_upper_limit>
            <other_analysis_desc>t=0.209; p=0.836</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.826</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=24</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.120</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.698</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.993</ci_lower_limit>
            <ci_upper_limit>1.233</ci_upper_limit>
            <other_analysis_desc>t=0.222; p=0.826</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ghuman-Folstein Screen for Social Interaction (SSI) Score, Pre- and Post-Intervention.</title>
        <description>The Ghuman-Folstein Screen for Social Interaction (SSI) assesses the change in behavior and temperament dysregulation as a total score.
The score ranges from 0-162, with 0 being most Impaired /has the strongest autism features and 162 having no impairment/no autism features.</description>
        <time_frame>Initial evaluation and at the end of the 3 month study. The test lasts 45 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive DM at baseline
dextromethorphan: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo at baseline
placebo: The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug Group at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to DM at 3 months</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to placebo at 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ghuman-Folstein Screen for Social Interaction (SSI) Score, Pre- and Post-Intervention.</title>
          <description>The Ghuman-Folstein Screen for Social Interaction (SSI) assesses the change in behavior and temperament dysregulation as a total score.
The score ranges from 0-162, with 0 being most Impaired /has the strongest autism features and 162 having no impairment/no autism features.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" spread="22.86"/>
                    <measurement group_id="O2" value="71.3" spread="17.26"/>
                    <measurement group_id="O3" value="73.1" spread="25.97"/>
                    <measurement group_id="O4" value="68.0" spread="16.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.80</ci_lower_limit>
            <ci_upper_limit>5.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Rett Syndrome Behavior Questionnaire Score, Pre- and Post-Intervention</title>
        <description>The Rett Syndrome Behavior Questionnaire (RSBQ) total score was assessed. The total score ranges from 0 to 90, with 0 exhibiting no Rett syndrome related symptoms and 90 showing the greatest amount of symptoms (worse outcome).</description>
        <time_frame>Initial evaluation and at the end of the 3 month study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive DM (dextromethorphan) at baseline: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo compound at baseline. The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug-dextromethorphan (DM) at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to receive DM (dextromethorphan) who completed study assessments at the 3 month time point.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group at 3 Months</title>
            <description>MECP2 positive subjects randomized to the placebo compound who completed the assessments at the 3 month time point.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rett Syndrome Behavior Questionnaire Score, Pre- and Post-Intervention</title>
          <description>The Rett Syndrome Behavior Questionnaire (RSBQ) total score was assessed. The total score ranges from 0 to 90, with 0 exhibiting no Rett syndrome related symptoms and 90 showing the greatest amount of symptoms (worse outcome).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8" spread="13.21"/>
                    <measurement group_id="O2" value="33.3" spread="12.26"/>
                    <measurement group_id="O3" value="33.8" spread="13.21"/>
                    <measurement group_id="O4" value="33.3" spread="12.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.73</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.02</ci_lower_limit>
            <ci_upper_limit>4.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in PedsQL School Functioning Subscale Score, Pre- and Post-Intervention</title>
        <description>Pediatric Quality of Life Inventory (PedsQL version 4). School Functioning subscale. 5-point Likert scale from 0 (Never) to 4 (Almost always); Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better Health Related Quality of Life (QOL).</description>
        <time_frame>Baseline evaluation and at the end of the 3 month study</time_frame>
        <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months, 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive dextromethorphan(DM) at baseline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug Group at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to DM at 3 months</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to placebo at 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PedsQL School Functioning Subscale Score, Pre- and Post-Intervention</title>
          <description>Pediatric Quality of Life Inventory (PedsQL version 4). School Functioning subscale. 5-point Likert scale from 0 (Never) to 4 (Almost always); Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better Health Related Quality of Life (QOL).</description>
          <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months, 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.231" spread="23.3682"/>
                    <measurement group_id="O2" value="49.583" spread="20.3793"/>
                    <measurement group_id="O3" value="55.769" spread="25.2782"/>
                    <measurement group_id="O4" value="44.592" spread="14.2084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.371</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=12</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>8.4615</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>32.8016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.3603</ci_lower_limit>
            <ci_upper_limit>28.2834</ci_upper_limit>
            <other_analysis_desc>t=0.903; p=0.371</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.358</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=11</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.9917</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>18.0163</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4553</ci_lower_limit>
            <ci_upper_limit>16.4387</ci_upper_limit>
            <estimate_desc>t=0.960; p=0.358</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in PedsQL Total Score, Pre- and Post-Intervention</title>
        <description>Pediatric Quality of Life Inventory (PedsQL version 4) total score. Each item is rated on a 5-point Likert scale from 0 (Never) to 4 (Almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. The Total Score is the sum of all the items over the number of items answered on all the Scales. Higher scores indicate better HRQOL.</description>
        <time_frame>Baseline evaluation and at the end of the 3 month study</time_frame>
        <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months, 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive dextromethorphan(DM) at baseline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug Group at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to DM at 3 months</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to placebo at 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PedsQL Total Score, Pre- and Post-Intervention</title>
          <description>Pediatric Quality of Life Inventory (PedsQL version 4) total score. Each item is rated on a 5-point Likert scale from 0 (Never) to 4 (Almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. The Total Score is the sum of all the items over the number of items answered on all the Scales. Higher scores indicate better HRQOL.</description>
          <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months, 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.018" spread="18.5915"/>
                    <measurement group_id="O2" value="54.157" spread="14.9519"/>
                    <measurement group_id="O3" value="50.9235" spread="19.11019"/>
                    <measurement group_id="O4" value="51.7286" spread="18.83983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.603</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=16</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.09412</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.06228</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.27756</ci_lower_limit>
            <ci_upper_limit>15.46580</ci_upper_limit>
            <estimate_desc>t=0.530; p=0.603</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.432</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=13</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.42857</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.21479</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.04665</ci_lower_limit>
            <ci_upper_limit>8.90380</ci_upper_limit>
            <estimate_desc>t=0.810; p=0.432</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in PedsQL Social Functioning Subscale Score, Pre- and Post-Intervention</title>
        <description>Pediatric Quality of Life Inventory (PedsQL version 4). Social Functioning subscale. 5-point Likert scale from 0 (Never) to 4 (Almost always); Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better Health Related Quality of Life (QOL).</description>
        <time_frame>Baseline and at the end of the 3 month trial</time_frame>
        <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months, 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive dextromethorphan(DM) at baseline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug Group at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to DM at 3 months</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to placebo at 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PedsQL Social Functioning Subscale Score, Pre- and Post-Intervention</title>
          <description>Pediatric Quality of Life Inventory (PedsQL version 4). Social Functioning subscale. 5-point Likert scale from 0 (Never) to 4 (Almost always); Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better Health Related Quality of Life (QOL).</description>
          <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months, 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.53" spread="21.849"/>
                    <measurement group_id="O2" value="54.64" spread="18.341"/>
                    <measurement group_id="O3" value="46.76" spread="16.002"/>
                    <measurement group_id="O4" value="47.14" spread="20.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.083</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=16</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>11.765</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>26.276</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.745</ci_lower_limit>
            <ci_upper_limit>25.275</ci_upper_limit>
            <other_analysis_desc>t=1.846; p=0.083</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=13</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>7.500</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.378</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.802</ci_lower_limit>
            <ci_upper_limit>15.802</ci_upper_limit>
            <other_analysis_desc>t=1.952; p=0.073</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in PedsQL Emotional Functioning Subscale Score, Pre- and Post-Intervention</title>
        <description>Pediatric Quality of Life Inventory (PedsQL version 4). Emotional Functioning subscale. 5-point Likert scale from 0 (Never) to 4 (Almost always); Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better Health Related Quality of Life (QOL).</description>
        <time_frame>Baseline evaluation and at the end of the 3 month study</time_frame>
        <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months, 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive DM (dextromethorphan) at baseline: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo compound at baseline. The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug-dextromethorphan (DM) at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to receive DM (dextromethorphan) who completed study assessments at the 3 month time point.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group at 3 Months</title>
            <description>MECP2 positive subjects randomized to the placebo compound who completed the assessments at the 3 month time point.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PedsQL Emotional Functioning Subscale Score, Pre- and Post-Intervention</title>
          <description>Pediatric Quality of Life Inventory (PedsQL version 4). Emotional Functioning subscale. 5-point Likert scale from 0 (Never) to 4 (Almost always); Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better Health Related Quality of Life (QOL).</description>
          <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months, 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.37" spread="17.979"/>
                    <measurement group_id="O2" value="68.93" spread="13.182"/>
                    <measurement group_id="O3" value="68.621" spread="24.3816"/>
                    <measurement group_id="O4" value="68.214" spread="113.8129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.549</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=18</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.7474</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>26.7110</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1269</ci_lower_limit>
            <ci_upper_limit>16.6217</ci_upper_limit>
            <estimate_desc>t=0.612; p=0.549</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.874</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=13</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.7143</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>16.5084</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.8174</ci_lower_limit>
            <ci_upper_limit>10.2460</ci_upper_limit>
            <estimate_desc>t=0.162; p=0.874</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in PedsQL Physical Functioning Subscale Score, Pre- and Post-Intervention</title>
        <description>Pediatric Quality of Life Inventory (PedsQL version 4). Physical Functioning subscale. 5-point Likert scale from 0 (Never) to 4 (Almost always); Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better Health Related Quality of Life (QOL).</description>
        <time_frame>Initial evaluation and at the end of the 3 month study</time_frame>
        <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months, 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive dextromethorphan(DM) at baseline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug Group at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to DM at 3 months</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to placebo at 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PedsQL Physical Functioning Subscale Score, Pre- and Post-Intervention</title>
          <description>Pediatric Quality of Life Inventory (PedsQL version 4). Physical Functioning subscale. 5-point Likert scale from 0 (Never) to 4 (Almost always); Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better Health Related Quality of Life (QOL).</description>
          <population>MECP2 Mutation positive participants who are fast metabolizers were randomized to placebo or DM at baseline. Two participants in the baseline DM group were noncompliant and removed from the study at baseline. At 3 months, 22 were analyzed in the DM study drug group and 25 in the placebo group due to incomplete data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.717" spread="30.3026"/>
                    <measurement group_id="O2" value="48.973" spread="29.5643"/>
                    <measurement group_id="O3" value="38.900" spread="29.7848"/>
                    <measurement group_id="O4" value="48.133" spread="34.9777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.693</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=17</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.8167</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>40.2609</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.2046</ci_lower_limit>
            <ci_upper_limit>23.8379</ci_upper_limit>
            <estimate_desc>t=0.402; p=0.693</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.909</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=14</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.8400</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>27.8994</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.6102</ci_lower_limit>
            <ci_upper_limit>16.2902</ci_upper_limit>
            <estimate_desc>t=0.117; p=0.909</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Seizure Frequency, Pre- and Post-Intervention, 0-4 Year Age Group</title>
        <description>Change in Frequency of seizure count baseline to follow-up for children aged 0-4 years</description>
        <time_frame>Baseline evaluation and at the end of the 3 month study</time_frame>
        <population>Children enrolled at baseline aged 0 to 4 years</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive DM
dextromethorphan: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo compound
placebo: The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug-dextromethorphan (DM) at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to DM at 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to placebo at 3 months,</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Seizure Frequency, Pre- and Post-Intervention, 0-4 Year Age Group</title>
          <description>Change in Frequency of seizure count baseline to follow-up for children aged 0-4 years</description>
          <population>Children enrolled at baseline aged 0 to 4 years</population>
          <units>seizure count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="1.41"/>
                    <measurement group_id="O2" value="3.2" spread="1.32"/>
                    <measurement group_id="O3" value="3.7" spread=".90"/>
                    <measurement group_id="O4" value="3.1" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.17</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Seizure Frequency, Pre-and Post-Intervention, 5-10 Year Age Group</title>
        <description>Change in Frequency of seizures baseline to follow-up for children aged 5-10 years</description>
        <time_frame>Baseline evaluation and at the end of the 3 month study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug-dextromethorphan (DM)</title>
            <description>MECP2 mutation positive subjects randomized to receive dextromethorphan(DM) at baseline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>MECP2 positive subjects randomized to the placebo at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Study Drug Group at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to DM at 3 months</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 3 Months</title>
            <description>MECP2 mutation positive subjects randomized to placebo at 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Seizure Frequency, Pre-and Post-Intervention, 5-10 Year Age Group</title>
          <description>Change in Frequency of seizures baseline to follow-up for children aged 5-10 years</description>
          <units>seizure count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.19"/>
                    <measurement group_id="O2" value="2.8" spread="1.47"/>
                    <measurement group_id="O3" value="3.36" spread="1.12"/>
                    <measurement group_id="O4" value="3.37" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Study Drug-dextromethorphan (DM)</title>
          <description>MECP2 mutation positive subjects randomized to receive dextromethorphan(DM) at baseline</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>MECP2 positive subjects randomized to the placebo at baseline.</description>
        </group>
        <group group_id="E3">
          <title>Study Drug Group at 3 Months</title>
          <description>MECP2 mutation positive subjects randomized to DM at 3 months</description>
        </group>
        <group group_id="E4">
          <title>Placebo at 3 Months</title>
          <description>MECP2 mutation positive subjects randomized to placebo at 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>increased platelets</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased alkaline phosphatase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sakkubai Naidu</name_or_title>
      <organization>Hugo W. Moser Research Institute at Kennedy Krieger , Inc.</organization>
      <phone>443 923 2778</phone>
      <email>naidu@kennedykrieger.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

